AlveoGene InGenuiTy™ technology includes a proprietary and validated next-generation lentiviral delivery platform originally developed by the GTC specifically targeted for the treatment of respiratory diseases with high unmet need.1
Unlike may current gene therapy approaches, which require administration via IV bolus, respiratory gene therapies developed using the InGenuiTy™ platform can be delivered through a nebuliser, directly targeting the lung. This facilitates the transduction of the lung epithelial cells with high efficiency, providing a long duration of action and sustaining these effects following repeated administration, if required.
AlveoGene also benefits from a comprehensive and interlinked IP estate with more than 10 patent families and reach through 2042. It is further underpinned by significant know-how, particularly in the scalable manufacturing processes for its viral vectors.
1 Excluding the use of the CFTR gene, which is mutated in cystic fibrosis